<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856023</url>
  </required_header>
  <id_info>
    <org_study_id>12PLK02</org_study_id>
    <nct_id>NCT01856023</nct_id>
  </id_info>
  <brief_title>HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma</brief_title>
  <acronym>PROCLIVITY02</acronym>
  <official_title>Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinigen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic&#xD;
      melanoma who are treatment naïve or have previously received a single non-immunologic&#xD;
      therapy.&#xD;
&#xD;
      Treatment Arm 1: Patients will receive two courses (four cycles) of High Dose Interleukin-2&#xD;
      (HD IL-2) followed by one course (four doses) of ipilimumab.&#xD;
&#xD;
      Treatment Arm 2: Patients will receive one course (four doses) of ipilimumab followed by two&#xD;
      courses (four cycles) of HD IL-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive IL-2 at 600,000 international units per kilogram (kg) by&#xD;
      intraveneous bolus (IVB) every 8 hours for 14 planned doses with an additional cycle 14 days&#xD;
      after the first. Ipilimumab 3mg/kg IV infusion Q3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual &amp; early closure&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year OS in the ITT population in each treatment arm</measure>
    <time_frame>One Year</time_frame>
    <description>Patients will be scheduled for four response assessments; Response assessment timing should be targeted to fall within the following time points: between 5-11 weeks, 13-19 weeks, 24-30 weeks and one year after initiating therapy in either treatment arm. Timing of the response assessments may be adjusted to facilitate clinical procedures and treatment decisions.&#xD;
Patient treatment tolerability and safety events will be monitored and managed while enrolled in the 12PLK02 study. Patients who receive HD IL-2 in the 12PLK02 study will be enrolled in the PROCLAIM study (Registry Protocol 10PLK13) for the collection of long-term assessment data, including response and disease status and treatment decisions. Patient treatment data will be entered in to the PROCLAIM database, for a minimum target of 2 years and potentially up to 5 years, after the patient completes the 12PLK02 study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Interleukin-2</intervention_name>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>Aldesleukin</other_name>
    <other_name>Proleukin</other_name>
    <other_name>interleukin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>anti-CTLA4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients 18 years or older&#xD;
&#xD;
          -  Confirmed and measurable metastatic melanoma with at least one measurable lesion for&#xD;
             evaluation of response&#xD;
&#xD;
          -  Meets the requirements for HD IL-2 therapy per Institutional guidelines&#xD;
&#xD;
          -  Meets the requirements for ipilimumab therapy per Institutional guidelines&#xD;
&#xD;
          -  Treatment naïve or has received only one systemic therapy apart from adjuvant therapy.&#xD;
&#xD;
          -  At least 4 weeks since last adjuvant therapy or other cancer treatment&#xD;
&#xD;
          -  Willing and able to give informed consent and participate in study procedures as&#xD;
             described in the 12PLK02 and 10PLK13 protocols. Patients consented for 12PLK02 will&#xD;
             also be asked to participate in the 10PLK13 PROCLAIM registry study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known or suspected infection with human immunodeficiency virus (HIV),&#xD;
             hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis&#xD;
&#xD;
          -  Pregnant, nursing or planning to become pregnant&#xD;
&#xD;
          -  Untreated brain metastases. (Brain metastases that have been treated, which no longer&#xD;
             require corticosteroid therapy and are without progression by MRI at least 6 weeks&#xD;
             after definitive therapy are acceptable.)&#xD;
&#xD;
          -  Received prior ipilimumab therapy (Prior Adjuvant Ipilimumab and Adjuvant Interferon&#xD;
             are permitted with a minimum 4 week washout)&#xD;
&#xD;
          -  Received prior HD IL-2 therapy.&#xD;
&#xD;
          -  Received investigational drug within 30 days prior to study dosing. Patients may&#xD;
             participate in non-interventional or observational clinical studies, including the&#xD;
             10PLK13 PROCLAIM registry study.&#xD;
&#xD;
          -  Concomitant disease or condition that would interfere with the conduct of the study or&#xD;
             that would, in the opinion of the Investigator, pose an unacceptable risk to the&#xD;
             patient in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sapna Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Sharfman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Lowder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prometheus Labs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MSMC Research Program</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, SC</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medicine</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists, Midwest Cancer Center - Legacy</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>metastatic</keyword>
  <keyword>skin cancer</keyword>
  <keyword>Stage IV</keyword>
  <keyword>interleukin-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

